Tampilkan postingan dengan label Kymriah. Tampilkan semua postingan
Tampilkan postingan dengan label Kymriah. Tampilkan semua postingan

Selasa, 12 September 2017

Developing a new drug does NOT cost $2.7 billion

Today's Managing Health Care Costs Number is $648 million


Source  Dark bars are R&D costs, while lighter bars are revenue.   One of 9 medications has not yet paid back its R&D costs 

JAMA Internal Medicine published an analysis of the cost of bringing a new cancer drug to market yesterday - and the cost is only 1/3 of what researchers at Tufts had previously estimated.  The researchers used SEC filings for 10 small companies which had no drugs on the market in 2007 - and divided the reported research and development costs of each company by the number of approved drugs to estimate total R&D cost.   The median estimated R&D cost was $648 million.

The  payoffs for these companies was enormous.  Total estimated R&D costs were $7.2 billion ($9.2 billion with discounting), and revenue for these drugs was $67 billion - and that revenue will continue for years to come.

This methodology to estimate research and development costs is not perfect.   It could substantially underestimate the cost to the extent that the researchers are only including companies that succeeded.    Many potential oncology drugs fail - and thus the researchers would not have been poring through their company's SEC 401K filings.  Further, companies expend resources on activities other than research to bring a drug to market.  On the other hand, the analysis doesn’t account for tax benefits for R&D -  which lower the cost substantially.

Most of the cost of developing new drugs is not due to regulations - and is especially not due to "excess regulation".  Half of these new medications were approved through the FDA's expedited process.  These drugs are indicated for small populations, so the FDA accepted studies that were small for their approval.

The New York Times has an article on its current electronic front page asserting that the $475, 000 cost of Kymriah will be the norm for gene therapy.  The article notes that there are 34 gene therapy drugs in the pipeline, and 470 in initial clinical trials. 

This research on the cost of new drug development helps show that such high prices are not "necessary" to support research and development.  But the pharmaceutical companies will continue to charge these high prices as long as they are able to.  We clearly need ceiling prices, barriers to approval based on initial price, or system-wide price negotiations if we don't want to see pharmaceutical costs continue to drive lack of health care affordability.


Jumat, 01 September 2017

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

Today's Managing Health Care Costs Number is $475,000

Personalized medicine is here - and it's a miracle.  Novartis' newly-approved drug Kymriah is genetically engineered immune cells from the patient which will kill leukemia cells, and it's shown remarkable efficacy in small trials.  One girl was dying of leukemia five years ago and remains in remission, and gave stirring testimony for the drug's approval before the FDA last month. (Photo of Emily Whitehead, above, is from the Associated Press via the NY Times)

This is just the beginning - training one's own immune cells to fight cancer (and possibly other diseases) holds enormous promise.  The cost: $475,000 for the one-time treatment.

Here are the reasons we shouldn't worry about that eye-popping cost

  • $475,000 is a small price to pay for a cure of an otherwise fatal disease- especially in a kid.  With a life expectancy of 70 years, this could mean the cost per Quality Adjusted  Life Year (QALY) is under $7000.
  • The drug has been approved for a rare cancer- with under 60 people likely to be eligible each year.  If all of them responded and paid full price, that's under $30 million.   Putting this in perspective, this is 0.0008% of national health care expenditures.
  • Novartis will restrict use to just 30-35 centers, so we won't have unqualified physicians prescribing this willy-nillly.  The engineered cells can cause life-threatening reactions - so this is an important safety measure
  • Novartis has promised refunds if there is no response in 1 month, and has also promised financial assistance for families without insurance coverage

You can probably guess that I'm worried, though.

Kymriah is the first of a set of CAR-T therapies - and there are a gaggle more on the way.  Some of them will be used for much more common conditions, and even Kymriah is likely to be used much more widely than the FDA-approved indications.   Gilead Pharmaceuticals just paid $11 billion for Kite, a cancer therapy company that has a CAR-T therapy tailored to non-Hodgkins Lymphoma expected to be approved in the next year.  The cost is likely to be similar, and the market larger. The total cost for CAR-T therapies will likely rise to many billions in just a few years.

Novartis has broken yet another price ceiling -and this will make it easier for the prices of other oncology medicines to continue to rise.   See this post for how this works with Multiple Sclerosis drugs.

Refunds for non-efficacy sound good in theory - but are often ineffective in practice.  This research showed "such schemes have poorly contributed to the fulfillment of the purpose in Italy, producing a trifling refund."

Financial assistance programs have largely been focused on maintaining price discipline - and have helped contribute to pharmaceutical company bottom lines by increasing revenue from other payers and offering the pharmas favorable tax treatment.

These genetically engineered cells will never be produced by a generic company - and are unlikely even to be produced as biosimilars for a long time if ever.   So if very high prices "stick," we should expect to pay them for the foreseeable future.

We should celebrate - this is an enormous feat of American medicine.  The initial research was performed at the University of Pennsylvania - but this drug would never had made it to market without the investment, trials, and regulatory work done by Novartis.

But we need to address drug prices if we are to control health care costs, and the high price set for Kymriah  is a bad omen.